| Cat. No. |
Product Name |
Information |
| PC-42616 |
Dinaciclib
CDK inhibitor
|
Dinaciclib (SCH 727965) is a potent and selective CDK inhibitor with IC50 of 1, 1, 3 and 4 nM against CDK2, CDK5, CDK1 and CDK9, respectively. |
| PC-45792 |
Roscovitine
CDK inhibitor
|
Roscovitine ((R)-Roscovitine, Seliciclib, CYC202) is a potent and selective CDK inhibitor with IC50 of 0.2 uM, 0.65 uM, and 0.7 uM for CDK5, Cdc2, and CDK2, respectively. |
| PC-42036 |
LY3177833
CDC7 inhibitor
|
LY3177833 is a potent and selective CDC7 inhibitor with IC50 of 3.3 nM. |
| PC-42060 |
AZD-5438
CDK1/2/9 inhibitor
|
AZD-5438 (AZD5438) potent and oral inhibitor of CDK1/2/9 with IC50 of 16/6/20 nM, respectively. |
| PC-42425 |
Senexin B
CDK8/CDK19 inhibitor
|
Senexin B (SNX2-1-165) is a highly potent, selective and orally available CDK8/CDK19 inhibitor with IC50 of 24-50 nM. |
| PC-42527 |
JNJ-7706621
CDK/Aurora inhibitor
|
JNJ-7706621 is a potent, dual CDK/Aurora kinase inhibitor with IC50 of 9/4/11/15 nM for CDK1/CDK2/Aurora A/Aurora B respectively. |
| PC-25879 |
ZLY025
cyclin K degrader
|
ZLY025 is a highly potent, selective Cyclin K (CCNK) degrader with DC50 of 42.7 nM and Dmax>93%, exhibits broad-spectrum antitumor activity. |
| PC-25728 |
NU6140
CDK2 inhibitor
|
NU6140 is a selective inhibitor of CDK2 with IC50 of 0.41 uM for CDK2-cyclin A, 10- to 36-fold selective for CDK2-cyclin A over the other CDKs. |
| PC-25672 |
LCI133
CDK4/6/9, AURKA/B inhibitor
|
LCI133 is a highly potent, selective multikinase CDK4/6/9 and AURKA/B inhibitor with IC50 of 4.7/10.2/4.1 nM for CDK4/6/9 and 2.8/10.6 nM for AURKA/B. |
| PC-25578 |
SNX9-1-20
CDK3 inhibitor
|
SNX9-1-20 is a potent, specific cyclin-dependent kinase 3 (CDK3) inhibitor with IC50 of 164 nM, inhibits CDK3/Cyclin E with IC50 of 0.47 uM (Rb-CTF) and 0.77 uM (Histone H1), highly selective over CDK2 (>50-fold). |
| PC-25577 |
SNX9
CDK3 inhibitor
|
SNX9 is a potent, specific cyclin-dependent kinase 3 (CDK3) inhibitor. |
| PC-25576 |
SNX9-1
CDK3 inhibitor
|
SNX9-1 is a potent, specific cyclin-dependent kinase 3 (CDK3) inhibitor with IC50 of 1.58 uM, is potent in preventing the induction of transcription by p21 (IC50=15.9 uM) and growth inhibition of the HT1080-based reporter cell line (IC50=9.3 uM). |
